학술논문
Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Document Type
Article
Author
Source
Subject
*CANCER treatment
*RENAL cell carcinoma
*PROTEIN-tyrosine kinases
*CARCINOGENESIS
*VASCULAR endothelial growth factor receptors
*CANCER invasiveness
*RENAL cancer patients
*
*
*
*
*
*
Language
ISSN
1464-4096
Abstract
Study Type - Therapy (individual cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Sorafenib is an oral receptor tyrosine kinase inhibitor that inhibits RAF serine/threonine kinases and receptor tyrosine kinases (vascular endothelial growth factor receptors 1, 2, 3 and platelet-derived growth factor-beta, Flt-3 and c-kit) that are implicated in tumourigenesis and tumour progression. Sorafenib is approved for the treatment of advanced renal cell cancer. B-RAF mutations (V600E and K601E) may be interesting negative predictive markers in metastatic kidney cancer patients treated with Sorafenib. Larger trials are needed to validate this hypothesis and should include B-RAF molecular analysis for better patient selection. OBJECTIVE [ABSTRACT FROM AUTHOR]